Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Neurobehavioral Effects of Interferon-α in Cancer Patients Phenomenology and Paroxetine Responsiveness of Symptom Dimensions

Capuron, L · 2002 · Neuropsychopharmacology

Abstract

We have previously shown that the risk of major depression in patients with malignant melanoma undergoing interferon-alpha (IFN-alpha) therapy can be reduced by pretreatment with the antidepressant, paroxetine. Using dimensional analyses, the present study assessed the expression and treatment responsiveness of specific clusters of neuropsychiatric symptoms over the first three months of IFN-alpha therapy. Forty patients with malignant melanoma eligible for IFN-alpha treatment were randomly assigned to receive either paroxetine or placebo in a double-blind design. Neuropsychiatric assessments were conducted at regular intervals during the first twelve weeks of IFN-alpha therapy and included the 21-item Hamilton Depression Rating Scale, the 14-item Hamilton Anxiety Rating Scale and the Neurotoxicity Rating Scale. Neurovegetative and somatic symptoms including anorexia, fatigue and pain appeared within two weeks of IFN-alpha therapy in a large proportion of patients. In contrast, symptoms of depressed mood, anxiety and cognitive dysfunction appeared later during IFN-alpha treatment and more specifically in patients who met DSM-IV criteria for major depression. Symptoms of depression, anxiety, cognitive dysfunction and pain were more responsive, whereas symptoms of fatigue and anorexia were less responsive, to paroxetine treatment. These data demonstrate distinct phenomenology and treatment responsiveness of symptom dimensions induced by IFN-alpha, and suggest that different mec…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0893-133x(01)00407-9

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

15 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 47 references

Cited by

See all 837

Metadata

Authors
Capuron, L.
Affiliations
Emory University (US)
Corresponding author
Capuron, L
Venue
Neuropsychopharmacology
Published
2002-05
Volume
26
Issue
5
Pages
643-652
ISSN
0893-133X (ISSN-L)
OpenAlex
W1969065116
Cited by
797
References
47
Citations by year
2026: 12 · 2025: 24 · 2024: 22 · 2023: 30 · 2022: 28 · 2021: 63 · 2020: 31 · 2019: 31 · 2018: 48 · 2017: 26 · 2016: 48 · 2015: 40 · 2014: 20 · 2013: 46 · 2012: 51
FWCI
10.25
Type
journal article
Language
en
Open access
closed
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
National Institute of Mental Health (MH-00680, MH 60723, R01MH060723)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
interferon-alpha, paroxetine, melanoma, major depressive disorder, neuropsychiatric symptoms, sickness behavior, cognitive impairment, anxiety, fatigue, anorexia, pain, antidepressant response, symptom phenomenology
MeSH terms
Adult, Aged, Analysis of Variance, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasms, Patients, Chi-Square Distribution, Interferon-alpha, Paroxetine, Antidepressive Agents, Second-Generation, Statistics, Nonparametric, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neurobehavioral Effects of Interferon-α in Cancer Patients Phenomenology and Paroxetine Responsiveness of Symptom Dimensions. https://app.cochat.ai/papers/10.1016/s0893-133x(01)00407-9
The paper
Capuron, L. (2002). Neurobehavioral Effects of Interferon-α in Cancer Patients Phenomenology and Paroxetine Responsiveness of Symptom Dimensions. Neuropsychopharmacology. https://doi.org/10.1016/s0893-133x(01)00407-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.